Drug Search Results
More Filters [+]

Ulinastatin

Alternative Names: ulinastatin
Latest Update: 2024-12-13
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Protease Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: China | India | Ukraine

Approved Indications: None

Known Adverse Events: None

Company: Zhejiang University
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ulinastatin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Injuries/wounds Unspecified|Pancreatitis|Shock, Septic|Coronary Artery Disease|Other|Reperfusion Injury|Congenital Heart Defects|Inflammation

Phase 3: Nasopharyngeal Cancer|Mucositis|Oral Ulcer|Sepsis|Stomatitis

Phase 2: Lung Injury|COVID-19|Respiratory Aspiration|Respiratory Distress Syndrome, Newborn|Acute Respiratory Distress Syndrome|Acute Lung Injury

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ChiCTR2300074837

N/A

Recruiting

Acute Kidney Injury|Coronary Disease|Kidney Diseases

2033-08-31

ChiCTR2300072139

N/A

Recruiting

Pancreatitis, Acute

2026-06-30

ChiCTR2400080349

N/A

Not yet recruiting

Sepsis

2025-12-31

ChiCTR2400091262

N/A

Not yet recruiting

Pancreatitis, Acute

2025-07-01

Recent News Events